On July 2, linvoseltamab-gcpt (Lynozyfic; Regeneron) received an accelerated approval from the FDA in relapsed/refractory ...

The newly FDA-approved linvoseltamab (Lynozyfic; Regeneron) may improve access to multiple myeloma treatment by offering an off-the-shelf, outpatient option that can be administered in community ...

Linvoseltamab combined with carfilzomib showed strong responses in R/R MM All treated patients (n=23) had previous exposure to PIs and more than half (n=12) were refractory to at least one PI.

Linvoseltamab has been granted Fast Track Designation and was accepted for Priority Review for the treatment of R/R MM by the FDA, with a target action date of August 22, 2024.

Linvoseltamab is an investigational bispecific antibody designed to bridge B-cell maturation antigen (BCMA) on multiple myeloma cells with CD3-expressing T cells to facilitate T-cell activation ...

Linvoseltamab is an investigational bispecific antibody designed to bridge B-cell maturation antigen (BCMA) on multiple myeloma cells with CD3-expressing T cells to facilitate local T-cell ...

Lynozyfic™ (linvoseltamab) Approved in the European Union for the Treatment of Relapsed/Refractory Multiple Myeloma Apr. 28, 2025 7:01 AM ET Regeneron Pharmaceuticals, Inc. (REGN) ...

Linvoseltamab is currently under clinical development, and its safety and efficacy have not been fully evaluated by any regulatory authority. About the Phase 1/2 Trial ...

Lynozyfic™ (linvoseltamab) Approved in the European Union for the Treatment of Relapsed/Refractory Multiple Myeloma Provided by GlobeNewswire Apr 28, 2025, 11:01:41 AM ...